Modern aspects of the pathogenesis and treatment of dyspepsia

A review of current data suggests that the attention to the problem of dyspepsia is huge. The definition of functional dyspepsia was given in the Rome IV criteria, according to which two of its main options are distinguished – epigastric pain syndrome and postprandial distress syndrome. The term “uninvestigated dyspepsia” is important, which means the presence of dyspepsia symptoms in patients who have not performed diagnostic procedures to identify the organic causes of the pathology. The prevalence of uninvestigated dyspepsia in the world is about 21%. The prevalence of functional dyspepsia is significantly lower than the prevalence of uninvestigated dyspepsia and fluctuates around 10%. The risk factors for dyspepsia are usually tobacco smoking, non-steroidal anti-inflammatory drugs and/or aspirin, and Helicobacter pylori infection. The concept of the pathogenesis of functional dyspepsia undergoes significant changes. By analogy with the pathophysiology of irritable bowel syndrome, lesions of the relationship between the modulation of the cerebral cortex and the signal system of the gastroduodenal zone, the association of sluggish immune inflammation in the duodenum with motility and sensory activity of the stomach are most actively studied. The treatment of functional dyspepsia is a complex problem and changes after new ideas about its pathogenesis. Modern meta-analyzes have made it possible to expand the indications for the proton pump inhibitors administration, which can be actively used not only for the treatment of epigastric pain syndrome, but also for postprandial distress syndrome. Along with the required Helicobacter pylori eradication, there are reasons for the use of probiotics and antibiotics for the dyspepsia treatment.

1. Ford A.C., Lacy B.E., Talley N.J. Irritable Bowel Syndrome. N Engl J Med. 2017;376(26):2566–2578. doi: 10.1056/NEJMra1607547.

2. Talley N.J., Ford A.C. Functional Dyspepsia. N Engl J Med. 2015;373(19):1853–1863. doi: 10.1056/NEJMra1501505.

3. Lacy B.E., Mearin F., Chang L., Chey W.D., Lembo A.J., Simren M., Spiller R. Bowel Disorders. Gastroenterology. 2016;150(6):1393–1407. doi: 10.1053/j.gastro.2016.02.031.

4. Stanghellini V., Chan F.K., Hasler W.L., Malagelada J.R., Suzuki H., Tack J., Talley N.J. Gastroduodenal Disorders. Gastroenterology. 2016;150(6):1380– 1392. doi: 10.1053/j.gastro.2016.02.011.

5. Simrén M., Törnblom H., Palsson O.S., Van Oudenhove L., Whitehead W.E., Tack J. Cumulative Effects of Psychologic Distress, Visceral Hypersensitivity, and Abnormal Transit on Patient-reported Outcomes in Irritable Bowel Syndrome. Gastroenterology. 2019;157(2):391–402. doi: 10.1053/j.gastro.2019.04.019.

6. Rasmussen S., Jensen T.H., Henriksen S.L., Haastrup P.F., Larsen P.V., Søndergaard J., Jarbøl D.E. Overlap of symptoms of gastroesophageal reflux disease, dyspepsia and irritable bowel syndrome in the general population. Scand J Gastroenterol. 2015;50(2):162–169. doi: 10.3109/00365521.2014.983157.

7. Talley N.J. What Causes Functional Gastrointestinal Disorders? A Proposed Disease Model. Am J Gastroenterol. 2020;115(1):41–48. doi: 10.14309/ajg.0000000000000485.

8. van Baar A.C.G., Nieuwdorp M., Holleman F., Soeters M.R., Groen A.K., Bergman J.J.G.H.M. The Duodenum harbors a Broad Untapped Therapeutic Potential. Gastroenterology. 2018;154(4):773–777. doi: 10.1053/j.gastro.2018.02.010.

9. Wauters L., Talley N.J., Walker M.M., Tack J., Vanuytsel T. Novel concepts in the pathophysiology and treatment of functional dyspepsia. Gut. 2020;69(3):591–600. doi: 10.1136/gutjnl-2019-318536.

10. Talley N.J., Vakil N.B., Moayyedi P. American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology. 2005;129(5):1756–1780. doi: 10.1053/j.gastro.2005.09.020.

11. Malfertheiner P., Megraud F., O’Morain C.A., Gisbert J.P., Kuipers E.J., Axon A.T. et al. Management of Helicobacter pylori infection-the Maastricht V/ Florence Consensus Report. Gut. 2017;66(1):6–30. doi: 10.1136/gutjnl-2016-312288.

12. Moayyedi P., Lacy B.E., Andrews C.N., Enns R.A., Howden C.W., Vakil N. ACG and CAG Clinical Guideline: Management of Dyspepsia. Am J Gastroenterol. 2017;112(7):988–1013. doi: 10.1038/ajg.2017.154.

13. Lazebnik L.B., Alekseenko S.A., Lyalukova E.A., Samsonov A.A., Bordin D.S., Tsukanov V.V. et al. Recommendations on management of primary care patients with symptoms of dyspepsia. Terapiya = Therapy. 2019;5(3):12–18. (In Russ.) doi: 10.18565/therapy.2019.3.12-19.

14. Ford A.C., Marwaha A., Sood R., Moayyedi P. Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis. Gut. 2015;64(7):1049–1057. doi: 10.1136/gutjnl-2014-307843.

15. Aziz I., Palsson O.S., Törnblom H., Sperber A.D., Whitehead W.E., Simrén M. Epidemiology, clinical characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults in the USA, Canada, and the UK: a cross-sectional population-based study. Lancet Gastroenterol Hepatol. 2018;3(4):252–262. doi: 10.1016/S2468-1253(18)30003-7.

16. Tsukanov V.V., Butorin N.N., Maady A.S., Shtygasheva O.V., Amelchugova O.S., Tonkikh J.L. et al. Helicobacter pylori Infection, Intestinal Metaplasia, and Gastric Cancer Risk in Eastern Siberia. Helicobacter. 2011;16(2):107– 112. doi: 10.1111/j.1523-5378.2011.00827.x.

17. Ageeva E.S., Shtygasheva O.V., Tsukanov V.V., Ryazantseva N.V. Immunological aspects of the clinical course of gastroduodenal diseases in residents of Khakassia. Immunologiya = Immunology. 2009;30(3):162– 164. (In Russ.) Available at: https://elibrary.ru/item.asp?id=12838762.

18. Ageyeva E.S., Shtygasheva O.V., Ryazantseva N.V., Tsukanov V.V. Molecular genetic factors affecting the outcome of Helicobacter pylori infection in residents of the Republic of Khakassia. Rossiyskiy zhurnal gastroehnterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Сoloproctology. 2010;20(4):16–21. (In Russ.) Available at: http://old-gastro-j.ru/article/244-molekulyarno-geneticheskie-faktoryi-vliyayuschie-na-ishod-infitsirovaniya-helicobacter-pylori-u-/show/full.

19. Shtygasheva O.V., Tsukanov V.V. Association of Cag A and Vac A strains of Helicobacter pylori and peptic ulcer in an organized population of Abakan. Rossiyskiy zhurnal gastroehnterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Сoloproctology. 2004;14(2):84–87. (In Russ.) Available at: https://elibrary.ru/item.asp?id=20446998.

20. Tsukanov V.V., Kasparov E.V., Tonkikh J.L. Shtygasheva O.V., Butorin N.N., Amelchugova O.S. et al. Peptic Ulcer Disease and Helicobacter pylori Infection in Different Siberian Ethnicities. Helicobacter. 2017;22(1):e12322. doi: 10.1111/hel.12322.

21. McMahon B.J., Bruce M.G., Koch A., Goodman K.J., Tsukanov V., Mulvad G. et al. The diagnosis and treatment of Helicobacter pylori infection in Arctic regions with a high prevalence of infection: Expert Commentary. Epidemiol Infect. 2016;144(2):225–233. doi: 10.1017/S0950268815001181.

22. Tsukanov V.V., Tonkikh J.L., Vasyutin A.V., Baron I.I. Prevalence, risk factors and clinical aspects of dyspepsia in residents of the Krasnoyarsk over 45 years old. Farmateka = Pharmateca. 2018;(9):62–65. (In Russ.) doi: 10.18565/pharmateca.2018.9.62-65.

23. Vanuytsel T., van Wanrooy S., Vanheel H., Vanormelingen C., Verschueren S., Houben E. et al. Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism. Gut. 2014;63(8):1293–1299. doi: 10.1136/gutjnl-2013-305690.

24. De Palma G., Blennerhassett P., Lu J., Deng Y., Park A.J., Green W. et al. Microbiota and host determinants of behavioural phenotype in maternally separated mice. Nat Commun. 2015;6:7735. doi: 10.1038/ncomms8735.

25. Lee I.S., Wang H., Chae Y., Preissl H., Enck P. Functional neuroimaging studies in functional dyspepsia patients: a systematic review. Neurogastroenterol Motil. 2016;28(6):793–805. doi: 10.1111/nmo.12793.

26. Walker M.M., Talley N.J. The Role of Duodenal Inflammation in Functional Dyspepsia. J Clin Gastroenterol. 2017;51(1):12–18. doi: 10.1097/MCG.0000000000000740.

27. Vanheel H., Vicario M., Vanuytsel T., Van Oudenhove L., Martinez C., Keita Å.V. et al. Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia. Gut. 2014;63(2):262–271. doi: 10.1136/gutjnl-2012-303857.

28. Beeckmans D., Riethorst D., Augustijns P., Vanuytsel T., Farré R., Tack J., Vanheel H. Altered Duodenal Bile Salt Concentration and Receptor Expression in Functional Dyspepsia. United European Gastroenterol J. 2018;6(9):1347–1355. doi: 10.1177/2050640618799120.

29. Cirillo C., Bessissow T., Desmet A.S., Vanheel H., Tack J., Vanden Berghe P. Evidence for neuronal and structural changes in submucous ganglia of patients with functional dyspepsia. Am J Gastroenterol. 2015;110(8):1205– 1215. doi: 10.1038/ajg.2015.158.

30. Talley N.J. Moving Away From Focussing on Gastric Pathophysiology in Functional Dyspepsia: New Insights and Therapeutic Implications. Am J Gastroenterol. 2017;112(1):141–144. doi: 10.1038/ajg.2016.519.

31. Tsukanov V.V., Kasparov E.V., Vasyutin A.V., Tonkikh J.L. Activation of the immune system and the possibility of its regulation to improve the effectiveness of the IBS treatment. Lechashchiy vrach = Attending Doctor. 2016;(8):24–27. (In Russ.) Available at: https://www.lvrach.ru/2016/08/15436528.

32. Pittayanon R., Yuan Y., Bollegala N.P., Khanna R., Leontiadis G.I., Moayyedi P. Prokinetics for Functional Dyspepsia. Cochrane Database Syst Rev. 2018;(10):CD009431. doi: 10.1002/14651858.CD009431.pub3.

33. Pinto-Sanchez M.I., Yuan Y., Hassan A., Bercik P., Moayyedi P. Proton Pump Inhibitors for Functional Dyspepsia. Cochrane Database Syst Rev. 2017;(11):CD011194. doi: 10.1002/14651858.CD011194.pub3.

34. Vandenberghe A., Schol J., Van den Houte K., Masuy I., Carbone F., Tack J. Current and emerging therapeutic options for the management of functional dyspepsia. Expert Opin Pharmacother. 2020;21(3):365–376. doi: 10.1080/14656566.2019.1707805.

35. Sugano K., Tack J., Kuipers E.J., Graham D.Y., El-Omar E.M., Miura S. et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353–1367. doi: 10.1136/gutjnl-2015-309252.

36. Igarashi M., Nakae H., Matsuoka T., Takahashi S., Hisada T., Tomita J., Koga Y. Alteration in the Gastric Microbiota and Its Restoration by Probiotics in Patients With Functional Dyspepsia. BMJ Open Gastroenterol. 2017;4(1):e000144. doi: 10.1136/bmjgast-2017-000144.

37. Tan V.P., Liu K.S., Lam F.Y., Hung I.F., Yuen M.F., Leung W.K. Randomised Clinical Trial: Rifaximin versus Placebo for the Treatment of Functional Dyspepsia. Aliment Pharmacol Ther. 2017;45(6):767–776. doi: 10.1111/apt.13945.

38. Ivashkin V.T., Mayev I.V., Sheptulin A.A., Lapina T.L., Trukhmanov A.S., Kartavenko I.M. et al. Diagnosis and treatment of the functional dyspepsia: clinical guidelines of the Russian Gastroenterological Association. Rossiyskiy zhurnal gastroehnterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Сoloproctology. 2017;27(1):50–61. (In Russ.) doi: 10.22416/1382-4376-2017-27-1-50-61.